ReviewFrontiers in immunology2023

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial.

Yan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.